Keyword Analysis & Research: summit therapeutics

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
summit therapeutics1.680.138836519
summit0.370.42697806
therapeutics1.120.349689512

Keyword Research: People who searched summit therapeutics also searched

Keyword CPC PCC Volume Score
summit therapeutics0.50.8970625
summit therapeutics stock21892512
summit therapeutics share price1.170.2226491
summit therapeutics news1.430.3304625
summit therapeutics plc0.680.9147475
summit therapeutics careers1.650.838163
summit therapeutics revenue1.620.2649527
summit therapeutics stock price0.060.3805332
summit therapeutics market cap1.560.1950317
summit therapeutics ticker0.480.5796219
summit therapeutics inc. smmt0.960.993851
summit therapeutics inc rights0.90.5796116
summit therapeutics inc1.10.8207548
summit therapeutics sub inc1.590.5163674
mrna therapeutics summit1.941238683
mrna based therapeutics summit1.880.450622
therapeutic health services summit1.580.1444348
stocks market summit therapeutics10.2743834
next generation protein therapeutics summit1.460.9479160

Search Results related to summit therapeutics on Search Engine

  • Home - Summit Therapeutics

    smmttx.com

    https://www.smmttx.com/

    WebSummit Therapeutics’ mission is to resolve serious, unmet medical needs for the betterment of overall human health. Summit’s leadership is committed to making a significant positive difference in the quality and potential duration of life for oncology patients facing difficult diagnoses.

    DA: 59 PA: 52 MOZ Rank: 77

  • About Us - Summit Therapeutics

    smmttx.com

    https://www.smmttx.com/our-company/about-us/

    WebOur mission is to make a significant difference for patients with high unmet medical needs, focusing on oncology. Our lead pipeline product candidate is a novel, bispecific antibody targeting both PD-1 and VEGF, ivonescimab.

    DA: 79 PA: 68 MOZ Rank: 89

  • Summit Therapeutics to Present at the Stifel 2024 Targeted …

    yahoo.com

    https://finance.yahoo.com/news/summit-therapeutics-present-stifel-2024-110000770.html

    WebApr 10, 2024 · Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal ...

    DA: 88 PA: 73 MOZ Rank: 14

  • Summit Therapeutics Inc. (SMMT) - Yahoo Finance

    yahoo.com

    https://finance.yahoo.com/quote/SMMT

    WebSummit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in...

    DA: 69 PA: 57 MOZ Rank: 76

  • Press Releases - Summit Therapeutics

    smmttx.com

    https://www.smmttx.com/press-releases/

    WebFeb 20, 2024 · Summit Therapeutics Announces Timing of Rights Offering for Up to $500 Million. January 20, 2023. Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody. January 5, 2023. Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference.

    DA: 63 PA: 33 MOZ Rank: 96

  • Summit Therapeutics Announces First Patient Treated in Phase …

    businesswire.com

    https://www.businesswire.com/news/home/20230509005525/en/Summit-Therapeutics-Announces-First-Patient-Treated-in-Phase-III-HARMONi-Clinical-Trial-Evaluating-Ivonescimab-SMT112

    WebMay 9, 2023 · MENLO PARK, Calif.-- ( BUSINESS WIRE )--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the first United States-based patient has been enrolled...

    DA: 27 PA: 43 MOZ Rank: 63

  • Summit Therapeutics Announces First Patient Treated in Phase …

    yahoo.com

    https://finance.yahoo.com/news/summit-therapeutics-announces-first-patient-113000584.html

    WebMay 9, 2023 · Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112) Business Wire. May 9, 2023 · 10 min read. Phase III Study Designed to...

    DA: 10 PA: 43 MOZ Rank: 63

  • Summit Therapeutics Announces Initial Indications for Clinical …

    businesswire.com

    https://www.businesswire.com/news/home/20230502005528/en/Summit-Therapeutics-Announces-Initial-Indications-for-Clinical-Trials-for-Ivonescimab-SMT112

    WebMay 3, 2023 · MENLO PARK, Calif.-- ( BUSINESS WIRE )--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has determined its first two indications in non-small...

    DA: 12 PA: 78 MOZ Rank: 96

  • Summit Therapeutics Announces Topline Results for Phase III

    globenewswire.com

    https://www.globenewswire.com/news-release/2021/12/20/2355247/0/en/Summit-Therapeutics-Announces-Topline-Results-for-Phase-III-Ri-CoDIFy-Study-for-C-Difficile-Infection.html

    WebCambridge, MA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced topline results for the Phase III Ri-CoDIFy study evaluating...

    DA: 85 PA: 98 MOZ Rank: 47

  • Summit Therapeutics Inc (SMMT) Stock Price & News - Google

    google.com

    https://www.google.com/finance/quote/SMMT:NASDAQ

    WebSummit Therapeutics Inc. $3.58. Apr 16, 3:29:10 PM GMT-4 · USD · NASDAQ · Disclaimer. 1D. 5D. 1M. 6M. YTD. 1Y. 5Y. MAX. search Compare to. TransMedics Group Inc. $93.58. TMDX1.92% Celsius...

    DA: 34 PA: 66 MOZ Rank: 4